PMID- 28489568
OWN - NLM
STAT- MEDLINE
DCOM- 20180425
LR  - 20220317
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 25
DP  - 2017 Jun 20
TI  - Efficacy and safety of decitabine in treatment of elderly patients with acute 
      myeloid leukemia: A systematic review and meta-analysis.
PG  - 41498-41507
LID - 10.18632/oncotarget.17241 [doi]
AB  - Elderly patients with acute myeloid leukemia (AML) have limited treatment options 
      concerned about their overall fitness and potential treatment related mortality. 
      Although a number of clinical trials demonstrated benefits of decitabine 
      treatment in elderly AML patients, the results remains controversial. A 
      meta-analysis was performed to evaluate efficacy and safety of decitabine in 
      treatment of elderly AML patients. Eligible studies were identified from PubMed, 
      Web of Science, Embase and Cochrane Library. Nine published studies were included 
      in the meta-analysis, enrolling 718 elderly AML patients. The efficacy outcomes 
      were complete remission (CR), overall response rate (ORR) and overall survival 
      (OS). Safety was evaluated based on treatment related grades 3-4 adverse events 
      (AEs) and early death (ED) rate. Pooled estimates with 95% confidence interval 
      (CI) for CR, ORR and OS were 27% (95% CI 19%-36%), 37% (95% CI 28%-47%) and 8.09 
      months (95% CI 5.77-10.41), respectively. The estimated treatment related early 
      death (ED) incidences were within 30-days 7% (95% CI 2%-11%) and 60-days 17% (95% 
      CI 11%-22%), respectively. Thrombocytopenia was the most common grades 3-4 AEs. 
      Subgroup analyses of age, cytogenetics risk, AML type and bone marrow blast 
      percentage showed no significant differences of treatment response to decitabine. 
      In conclusion, decitabine is an effective and well-tolerated therapeutic 
      alternative with acceptable side effects in elderly AML patients.
FAU - He, Pin-Fang
AU  - He PF
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang 
      212002, Jiangsu, P.R. China.
AD  - The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang 
      212002, Jiangsu, P.R. China.
FAU - Zhou, Jing-Dong
AU  - Zhou JD
AD  - Department of Hematology, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang 212002, Jiangsu, P.R. China.
FAU - Yao, Dong-Ming
AU  - Yao DM
AD  - Department of Clinical Laboratory, Affiliated People's Hospital of Jiangsu 
      University, Zhenjiang 212002, Jiangsu, P.R. China.
FAU - Ma, Ji-Chun
AU  - Ma JC
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang 
      212002, Jiangsu, P.R. China.
AD  - The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang 
      212002, Jiangsu, P.R. China.
FAU - Wen, Xiang-Mei
AU  - Wen XM
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang 
      212002, Jiangsu, P.R. China.
AD  - The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang 
      212002, Jiangsu, P.R. China.
FAU - Zhang, Zhi-Hui
AU  - Zhang ZH
AD  - Department of Hematology, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang 212002, Jiangsu, P.R. China.
FAU - Lian, Xin-Yue
AU  - Lian XY
AD  - Department of Hematology, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang 212002, Jiangsu, P.R. China.
FAU - Xu, Zi-Jun
AU  - Xu ZJ
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang 
      212002, Jiangsu, P.R. China.
AD  - The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang 
      212002, Jiangsu, P.R. China.
FAU - Qian, Jun
AU  - Qian J
AD  - Department of Hematology, Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang 212002, Jiangsu, P.R. China.
FAU - Lin, Jiang
AU  - Lin J
AD  - Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang 
      212002, Jiangsu, P.R. China.
AD  - The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang 
      212002, Jiangsu, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - Aged
MH  - Antimetabolites, Antineoplastic/*therapeutic use
MH  - Azacitidine/*analogs & derivatives/therapeutic use
MH  - Decitabine
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/pathology
MH  - Male
PMC - PMC5522197
OTO - NOTNLM
OT  - acute myeloid leukemia (AML)
OT  - decitabine
OT  - elderly patient
OT  - meta-analysis
OT  - systematic review
COIS- CONFLICTS OF INTEREST The authors declare that they have no conflicts of 
      interest.
EDAT- 2017/05/11 06:00
MHDA- 2018/04/26 06:00
PMCR- 2017/06/20
CRDT- 2017/05/11 06:00
PHST- 2016/12/08 00:00 [received]
PHST- 2017/04/11 00:00 [accepted]
PHST- 2017/05/11 06:00 [pubmed]
PHST- 2018/04/26 06:00 [medline]
PHST- 2017/05/11 06:00 [entrez]
PHST- 2017/06/20 00:00 [pmc-release]
AID - 17241 [pii]
AID - 10.18632/oncotarget.17241 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jun 20;8(25):41498-41507. doi: 10.18632/oncotarget.17241.